Skip to content
RDL Network logo
The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: A Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group — G.F. Samelis (2005) | RDL Network